PERITONEAL CANCER

This study tests whether adding oregovomab to the standard drug niraparib can help control platinum-sensitive recurrent ovarian cancer. Ten adults whose cancer returned after initial chemotherapy will receive both drugs. The goal is to see if the combination shrinks tumors or kee…

This study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors and control the disease. Participants …

This study tests whether giving chemotherapy before and after surgery (plus heated chemotherapy during surgery) helps people with colorectal cancer that has spread to the abdomen lining live longer compared to surgery alone. About 358 adults with resectable cancer will be randoml…

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study looks at how to quickly identify depression in women with ovarian, peritoneal, or fallopian tube cancer. It compares a special support program with enhanced standard care to see which better improves quality of life. About 409 women on active cancer treatment are takin…

This study tests whether a reminder sent to doctors can increase the number of patients with suspicious ovarian masses who are referred to a gynecologic oncology specialist within 30 days. About 20 women with concerning imaging results will be included, and their referral rates w…